Study finds weekly GLP-1 added to therapy further cuts heavy drinking

Researchers reported on April 30, 2026, that adding a weekly GLP-1 receptor agonist to cognitive behavioral therapy led to greater reductions in heavy drinking than cognitive behavioral therapy by itself ^[1][2]. The finding was listed as a new research development in the official FDA approval histories for both Wegovy and Ozempic, two semaglutide products made by Novo Nordisk ^[1][2]. The sources available for this article do not include the specific patient counts, drinking-reduction percentages, or trial design details from the study itself, so those numbers are not yet known from what has been published in the material reviewed here.

What is clear from the drug histories is that semaglutide, sold under the brand names Wegovy, Ozempic, and Rybelsus, does not carry an FDA-approved indication for alcohol use disorder. Wegovy is approved for weight management, cardiovascular risk reduction in people with obesity or overweight and existing heart disease, and for a liver condition called MASH ^[1]. Ozempic is approved for type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, and to slow kidney disease in people with type 2 diabetes and chronic kidney disease ^[2]. Neither approval history lists alcohol use disorder as a treatment use ^[1][2].

This pattern fits a broader trend the sources confirm: semaglutide has picked up several new approved uses over time. It went from a diabetes drug approved in 2017 to a weight-loss drug approved in 2021, then added cardiovascular risk reduction in 2024, a MASH liver indication in 2025, and a kidney disease indication in early 2025 ^[1][2]. The alcohol-use study reported in April 2026 fits into this same period of expanding research interest in GLP-1 drugs, but it stands apart because it is investigational research, not a step toward a new FDA label, according to the summary of this development.

Why it matters for patients

For people currently taking Wegovy, Ozempic, or Rybelsus for an approved use, this study does not change anything about how those drugs are prescribed or labeled. The FDA approval histories confirm that alcohol use disorder is not among the conditions these semaglutide products are approved to treat ^[1][2].

For people who drink heavily and are curious whether a GLP-1 drug could help, the honest answer right now is that the science is still investigational. A study finding that a weekly GLP-1 added to therapy reduced heavy drinking more than therapy alone is a research result, not a treatment recommendation, and the specific trial details -- how many people took part, how much drinking dropped, and which GLP-1 drug was used -- are not detailed in the sources reviewed for this article.

People considering off-label use of any GLP-1 medicine for a condition it is not approved for should know that off-label use carries its own set of unknowns, including whether insurance would cover it and whether long-term safety in that context has been studied. The approval histories for Wegovy and Ozempic list boxed warnings for thyroid C-cell tumors and other precautions tied to their approved uses, but those warnings were studied in the context of diabetes, obesity, and related conditions, not alcohol use disorder ^[1][2].

What happens next

The sources reviewed here do not specify a timeline for further trials, an FDA submission, or a possible new indication tied to alcohol use disorder. Novo Nordisk's public drug histories show a steady cadence of new data releases and approvals through the first months of 2026, including new dosing forms and pricing changes for its semaglutide products ^[1][2], suggesting more updates on GLP-1 research are likely to follow, though none are confirmed yet for alcohol use disorder specifically.